Abivax SA announced the election of Sylvie Grégoire as the new Chair of the Abivax Board of Directors, taking over for current CEO and Interim Chair, Marc de Garidel. With Ms. Grégoire joining the Board of Directors, Carol Brosgart, MD will be resigning from the Abivax Board. The appointment of Dr. Sylvie Grégoire as Chair of the Board of Directors effective immediately.

Dr. Grégoire is a distinguished pharmaceutical and biotech executive with over 30 years in international leadership roles. Her expertise encompasses late-stage development, financial raises and commercial expansion. Dr. Grégoire is the Co-Founder and was Executive Chair of the Board at EIP Pharma Inc., based in Boston, MA.

Under her leadership, EIP Pharma transitioned into CervoMed. Dr. Grégoire has previously served on the board of Cubist, Glycofi, Vifor Pharma, Revvity and chaired the board of IDM Pharma, Corvidia and CervoMed. Dr. Grégoire is currently a member of the board of Novo Nordisk, CervoMed and F2G Ltd. Dr. Carol Brosgart has announced her resignation from the board.

Dr. Brosgart joined the Abivax board in 2018. The company also announced the appointment of Dr. Fabio Cataldi as Chief Medical Officer. Dr. Cataldi joins Abivax with more than 20 years of successful experience in the development and commercialization of innovative therapies.

He brings deep clinical, medical and scientific knowledge and expertise in immunology and gastroenterology, having served in senior research and development roles at Arena Pharmaceuticals, AbbVie, Shire, Pfizer, Biogen and Novartis. Most recently he held the role of CMO at Landos BioPharma until the successful sale to AbbVie. Dr. Cataldi will have internal responsibility for Clinical Operations, Clinical Development, Pharmacovigilance and Medical Affairs.

Additionally, David Zhang, Ph.D will join Abivax as Chief Strategy Officer. Dr. Zhang joins Abivax from Alumis, where he held the role of Chief Information Officer responsible for building up capabilities in Biometrics, IT, Facilities and Investor Relations during the early days of the company. Before Alumis, Dr. Zhang held the role of Vice President of Biometrics and Digital Health at Myokardia where he played a pivotal role in the study design, data read-out, and New Drug Application submission for Camyzos.

Dr. Zhang will have internal responsibility for Biometrics, Quality, HEOR and Regulatory. The Company also announced Dr. Sheldon Sloan, MD, M Bioethics will be leaving his role as Chief Medical Officer. After 37 years of clinical medicine and various roles in the Pharmaceutical Industry, Dr. Sloan has decided to retire.

We deeply appreciate all his contributions to Abivax and to the ABTECT program which include recruiting and building the medical team functions of Pharmacovigilance, Clinical Development, Clinical Pharmacology, Biometrics and Medical Affairs. The Company also announced that Chief Commercial Officer Michael Ferguson has left the organization to pursue other opportunities.